Photo by bermixstudio from unsplash
In a retrospective single-center review of patients with myeloma treated with the immunomodulatory drug thalidomide, lenalidomide, or pomalidomide, the authors report that marked hyperpigmentation occurred in 40% of Black patients,… Click to show full abstract
In a retrospective single-center review of patients with myeloma treated with the immunomodulatory drug thalidomide, lenalidomide, or pomalidomide, the authors report that marked hyperpigmentation occurred in 40% of Black patients, compared with 3.5% of White patients. Since only 2% of the participants in the original pivotal trial of lenalidomide were Black, this unexpectedly high rate was not previously recognized.
Keywords:
black patients;
skin hyperpigmentation;
patients receiving;
hyperpigmentation;
hyperpigmentation black;
incidence skin
Journal Title: Blood
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!